CXCR4 and neoplasm: Treatment of mice inoculated with the ovarian cancer line BR5-1, with a specific antagonist for CXCR4, leads to increased tumor death, tissue necrosis, decreased intra-peritoneal disease burden, increased recruitment of tumor specific effector T cells, reduction in intratumoral Treg, and significantly increased survival (33).